- The Group has a robust process to identify and assess opportunities, using clear criteria such as consideration of geographic expansion, portfolio or brand growth, pipeline and NPD development and financial performance
- In June 2025, Animalcare acquired a 25% strategic equity stake in InVetro, an Australia-based Companion Animal health business for AUD$3m, fully aligned with the Group’s M&A requirements and growth ambitions. The agreement includes a call option for Animalcare to increase its holding in InVetro to 51% in 2029
Our strategic rationale is clear:
- The investment expands Animalcare’s presence in the growing Asia-Pacific veterinary market, building on its acquisition of Randlab completed on 3 January 2025
- There is a low overlap between InVetro and Animalcare’s existing portfolio, providing an opportunity for Animalcare to expand the reach of its existing portfolio into Australia and Asia-Pacific, as well as bring InVetro’s new product development to Europe as this progresses
- There is the potential for synergies in bringing products to new geographic markets
- InVetro has a strong and capable team as well as clear growth plans for long-term value creation